The Iran Project
: The Atomic Energy Organization of Iran (AEOI) has unveiled its latest diagnostic radiopharmaceutical for prostate cancer.
Tuesday 16 January 2024 - 18:17
Story Code : 412232
Source : Mehr News
AEOI unveils radiopharmaceutical for prostate cancer
The new radiopharmaceutical, named PARS-TECTO-PSMA, was introduced by Pars Isotope Company.
Synthesized and formulated for the first time by domestic experts, the kit provides the capability for faster and more cost-effective prostate cancer diagnosis in the early stages using a new imaging method called SPECT (Single Photon Emission Computed Tomography).
The radiopharmaceutical specifically attaches to prostate cancer receptors in the body, offering more accurate information to the treating physician about the size and location of the tumor compared to previous methods.
The innovation enhances the monitoring and observation of the patient's recovery process as well.
Reporter : Editorial of The Iran Project
# Tags
